S&P 500   3,204.54 (-0.68%)
DOW   26,685.39 (-0.69%)
QQQ   257.83 (-1.18%)
AAPL   384.55 (-1.62%)
MSFT   203.94 (-1.97%)
FB   238.68 (-0.67%)
GOOGL   1,503.63 (-0.87%)
AMZN   2,987.00 (-0.73%)
NVDA   403.06 (-1.47%)
CGC   17.96 (-1.05%)
BABA   243.12 (-2.44%)
MU   49.96 (-1.09%)
GE   7.10 (-0.56%)
TSLA   1,507.82 (-2.47%)
AMD   54.50 (-1.52%)
T   30.31 (+1.00%)
ACB   12.22 (-5.05%)
F   6.80 (+0.89%)
GILD   76.12 (-0.69%)
DIS   119.36 (-1.27%)
NFLX   521.61 (-0.32%)
BAC   24.01 (-2.40%)
BA   180.84 (-3.78%)
S&P 500   3,204.54 (-0.68%)
DOW   26,685.39 (-0.69%)
QQQ   257.83 (-1.18%)
AAPL   384.55 (-1.62%)
MSFT   203.94 (-1.97%)
FB   238.68 (-0.67%)
GOOGL   1,503.63 (-0.87%)
AMZN   2,987.00 (-0.73%)
NVDA   403.06 (-1.47%)
CGC   17.96 (-1.05%)
BABA   243.12 (-2.44%)
MU   49.96 (-1.09%)
GE   7.10 (-0.56%)
TSLA   1,507.82 (-2.47%)
AMD   54.50 (-1.52%)
T   30.31 (+1.00%)
ACB   12.22 (-5.05%)
F   6.80 (+0.89%)
GILD   76.12 (-0.69%)
DIS   119.36 (-1.27%)
NFLX   521.61 (-0.32%)
BAC   24.01 (-2.40%)
BA   180.84 (-3.78%)
S&P 500   3,204.54 (-0.68%)
DOW   26,685.39 (-0.69%)
QQQ   257.83 (-1.18%)
AAPL   384.55 (-1.62%)
MSFT   203.94 (-1.97%)
FB   238.68 (-0.67%)
GOOGL   1,503.63 (-0.87%)
AMZN   2,987.00 (-0.73%)
NVDA   403.06 (-1.47%)
CGC   17.96 (-1.05%)
BABA   243.12 (-2.44%)
MU   49.96 (-1.09%)
GE   7.10 (-0.56%)
TSLA   1,507.82 (-2.47%)
AMD   54.50 (-1.52%)
T   30.31 (+1.00%)
ACB   12.22 (-5.05%)
F   6.80 (+0.89%)
GILD   76.12 (-0.69%)
DIS   119.36 (-1.27%)
NFLX   521.61 (-0.32%)
BAC   24.01 (-2.40%)
BA   180.84 (-3.78%)
S&P 500   3,204.54 (-0.68%)
DOW   26,685.39 (-0.69%)
QQQ   257.83 (-1.18%)
AAPL   384.55 (-1.62%)
MSFT   203.94 (-1.97%)
FB   238.68 (-0.67%)
GOOGL   1,503.63 (-0.87%)
AMZN   2,987.00 (-0.73%)
NVDA   403.06 (-1.47%)
CGC   17.96 (-1.05%)
BABA   243.12 (-2.44%)
MU   49.96 (-1.09%)
GE   7.10 (-0.56%)
TSLA   1,507.82 (-2.47%)
AMD   54.50 (-1.52%)
T   30.31 (+1.00%)
ACB   12.22 (-5.05%)
F   6.80 (+0.89%)
GILD   76.12 (-0.69%)
DIS   119.36 (-1.27%)
NFLX   521.61 (-0.32%)
BAC   24.01 (-2.40%)
BA   180.84 (-3.78%)
Log in

Retrophin (NASDAQ:RTRX) Rating Increased to Strong-Buy at Zacks Investment Research

Last updated on Wednesday, July 15, 2020 | 2020 MarketBeat

Retrophin (NASDAQ:RTRX) was upgraded by Zacks Investment Research from a "hold" rating to a "strong-buy" rating in a research note issued on Wednesday, Zacks.com reports. The firm presently has a $23.00 price objective on the biopharmaceutical company's stock. Zacks Investment Research's price objective indicates a potential upside of 12.69% from the company's current price.

According to Zacks, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. "

Several other research analysts have also issued reports on RTRX. BMO Capital Markets dropped their price target on shares of Retrophin from $34.00 to $31.00 in a research report on Monday. Canaccord Genuity reissued a "buy" rating and issued a $26.00 price target on shares of Retrophin in a research report on Tuesday, May 19th. ValuEngine lowered shares of Retrophin from a "strong-buy" rating to a "buy" rating in a research report on Friday, April 17th. BidaskClub raised shares of Retrophin from a "hold" rating to a "buy" rating in a report on Saturday, June 27th. Finally, BTIG Research started coverage on shares of Retrophin in a report on Tuesday, June 16th. They set a "buy" rating and a $25.00 price objective for the company. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. The company presently has a consensus rating of "Buy" and an average price target of $27.00.

NASDAQ:RTRX opened at $20.41 on Wednesday. Retrophin has a 12-month low of $8.98 and a 12-month high of $21.91. The company has a quick ratio of 5.88, a current ratio of 5.97 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $864.84 million, a PE ratio of -8.33 and a beta of 0.86. The firm has a 50-day moving average price of $17.54 and a 200 day moving average price of $15.79.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.68) by $0.70. Retrophin had a negative net margin of 57.01% and a negative return on equity of 43.15%. The firm had revenue of $47.77 million during the quarter, compared to analyst estimates of $43.14 million. On average, research analysts expect that Retrophin will post -1.56 EPS for the current year.

In related news, Director Steve Aselage sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the sale, the director now owns 238,732 shares of the company's stock, valued at $4,774,640. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 16,364 shares of company stock valued at $298,850. 4.63% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of RTRX. Great West Life Assurance Co. Can acquired a new stake in shares of Retrophin in the fourth quarter valued at approximately $50,000. Credit Suisse AG increased its holdings in shares of Retrophin by 21.4% in the fourth quarter. Credit Suisse AG now owns 41,786 shares of the biopharmaceutical company's stock valued at $593,000 after purchasing an additional 7,374 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Retrophin by 20.0% in the fourth quarter. Renaissance Technologies LLC now owns 816,827 shares of the biopharmaceutical company's stock valued at $11,599,000 after acquiring an additional 135,902 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Retrophin by 16.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 19,062 shares of the biopharmaceutical company's stock valued at $271,000 after acquiring an additional 2,652 shares during the last quarter. Finally, Oxford Asset Management LLP boosted its stake in Retrophin by 685.7% in the fourth quarter. Oxford Asset Management LLP now owns 103,202 shares of the biopharmaceutical company's stock valued at $1,465,000 after acquiring an additional 90,067 shares during the last quarter.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Read More: What is the Quick Ratio?

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Stocks That Prove Dividends Matter

Dividends can be an equalizing factor when comparing stocks. For example, you can be looking at one stock that is up 5% and another that is up 7% over a period of time. However, the stock that is up 5% pays a dividend while the one that pays 7% does not. That dividend factors into the stock’s total return. Therefore although the former would appear to offer a better return, the stock that pays a dividend may actually provide a higher total return.

Dividends are a portion of a company’s profit reflected as a percentage. However, this percentage changes with the company’s stock price. For that reason, a common mistake investors make is to chase a yield. But a company that pays a 4% dividend yield may be a far better investment than a company with an 8% yield. Here’s why.

The most important attribute of a dividend is its reliability. Getting a solid dividend one year has very little meaning if the company has to suspend, or cut, its dividend the next year. Investors want to own stocks in companies that have a solid history of paying a regular dividend. Another important consideration is a company’s ability to increase its dividend. This means that the company is increasing the amount of the dividend regardless of stock price. Companies that do this over a specific period of time have achieved a special status. Dividend Aristocrats are companies that have increased their dividend every year for at least the last 25 years. Dividend Kings have increased their dividends every year for at least the last 50 years.

In this presentation, we highlight seven companies that offer a nice dividend and the opportunity for decent growth.

Click on Continue to view the “7 Stocks That Prove Dividends Matter”.

View the "7 Stocks That Prove Dividends Matter".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.